SCHEDULE: Janus Henderson Boosts Akero Therapeutics Stake to 7.9%

Janus Henderson Group plc has reported an increased beneficial ownership of 7.9% in Akero Therapeutics, Inc., holding 6,280,305 ordinary shares.

Summary

• Janus Henderson Group plc, an investment adviser and parent holding company, reported beneficial ownership of 6,280,305 ordinary shares in Akero Therapeutics, Inc.
• This aggregate ownership represents 7.9% of Akero Therapeutics' ordinary shares outstanding.
• The filing is an Amendment No. 11 to a Schedule 13G, indicating an update to a previously reported stake.
• Janus Henderson's subsidiary, JHIUS, is deemed the beneficial owner of 6,193,569 shares, representing 7.7% of the class.
• Other indirect subsidiaries, JHIUKL and JHIAIFML, are also registered investment advisers furnishing investment advice to Managed Portfolios.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a routine beneficial ownership report (Schedule 13G Amendment), which is primarily factual and does not inherently convey positive or negative sentiment regarding the issuer's operational performance or future prospects. It simply reports an institutional investor's stake.

Positives

• A significant institutional investor, Janus Henderson Group plc, maintains a substantial stake in Akero Therapeutics, which can be viewed as a vote of confidence in the company.

Future Outlook

NA

Management Comments

• I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

NA

Stakeholder Impact

• Shareholders of Akero Therapeutics: The continued significant ownership by a major institutional investor like Janus Henderson Group plc may be viewed positively as a vote of confidence in the company's long-term prospects.
• Janus Henderson Group plc: The filing reflects their ongoing investment strategy and compliance with regulatory reporting requirements for their managed portfolios.

Key Dates

Keywords

Akero Therapeutics, Janus Henderson Group, Beneficial Ownership, Schedule 13G, Ordinary Shares, Institutional Investment, Investment Adviser, AKRO